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Prospective decision analysis for peripheral
vascular disease predicts future quality of life
Thomas E. Brothers, MD, Jacob G. Robison, MD, and Bruce M. Elliott, MD, Charleston, SC
Objective: Decision making for peripheral vascular disease can be quite complex as a result of pre-existing compromise of
patient functional status, anatomic considerations, uncertainty of favorable outcome, medical comorbidities, and
limitations in life expectancy. The ability of prospective decision-analysis models to predict individual quality of life in
patients with lower extremity arterial occlusive disease was tested.
Methods: This was a prospective cohort study. The settings were university and Veterans Administration vascular surgery
practices. All 214 patients referred with symptomatic lower extremity arterial disease of any severity over a 2-year period
were screened, and 206 were enrolled. A Markov model was compared with standard clinical decision-making. Utility
assessment and generalized (Short Form-36; SF-36) and disease-specific (Walking Impairment Questionnaire; WIQ)
quality of life were derived before treatment. Estimates of treatment outcome probabilities and intended and actual
treatment plans were provided by attending vascular surgeons. Themain outcomemeasures were generalized (SF-36) and
disease-specific (WIQ) variables at study entry and at 4 and 12 months.
Results: Primary intervention consisted of amputation for 9, bypass for 42, angioplasty for 8, and medical treatment for
147 patients. Considering all patients, no improvement in mean overall patient quality of life measured by the SF-36
Physical Component Score (27 8 vs 28 8; P .87) or WIQ (39 22 vs 39 23; P .13) was noted 12 months after
counseling and treatment by the vascular surgeons. Individually considered SF-36 categories were improved only for
Bodily Pain (40 23 vs 49 25; P .03), with themost significant improvement observed among patients with themost
severe pain (68  25 vs 37  23; P  .02) and among those undergoing bypass (60  29 vs 31  22; P  .02). It is
noteworthy that when the treatment chosen was incongruent with the Markov model, patients were more likely to report
a poorer quality of life at 1 year (Physical Component Score, 25  8 vs 29  8; P < .001). The quality of life predicted
at baseline by the Markov model correlated positively with the Physical Component Score (r  0.23), Bodily Pain (r 
0.33), and Fatigue (r  0.44) and negatively with WIQ (r  0.08) observed 1 year later.
Conclusions: Prospective application of an individualized decision Markov model in patients with vascular disease was
predictive of patient quality of life at 1 year. The patient’s outcome was worse when the treatment received did not follow
the model’s recommendation. This decision analysis model may be useful to identify patients at risk for poor outcomes
with standard clinical decision making. (J Vasc Surg 2007;46:701-8.)Graft or arterial occlusion and progressive compromise
of distal arterial outflow threaten patient quality of life after
intervention for peripheral arterial occlusive disease of the
lower extremities.1-3 Wound breakdown, infection, or ex-
tensive gangrene may mandate amputation even when the
reconstruction remains patent. Few patients who are
nonambulatory before intervention resume their ambula-
tory status.4,5 Pre-existing compromise of patient func-
tional status, anatomic considerations, uncertainty of favor-
able outcome, medical comorbidities, and limitations in
patient life expectancy all serve to make the decision to
intervene quite complex. Typically, surgeons advise their
patients on the basis of published reports of the outcomes
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doi:10.1016/j.jvs.2007.05.045of intervention melded with their own subjective assess-
ment of the patient’s needs. Unfortunately, this strategy is
vulnerable to improper interpretation and application of
the available data by the surgeon and unrealistic expecta-
tions by the patient.
Various methods to codify vascular treatment decisions
to optimize patient quality of life have been reported.6,7
Decision analysis is one set of tools developed by health care
researchers to evaluate complex medical decisions.8-11 We
have previously examined the use of individualized decision
analysis in patients with chronic peripheral vascular occlu-
sive disease scheduled to undergo bypass operation.12
Among this group, the chance of a favorable long-term
outcome was much greater when the decision analysis
model agreed with bypass as the best therapy compared
with when it favored a different intervention (80% vs 50%
“good”), thus identifying a subgroup of patients less likely
to benefit from bypass operation. We subsequently ex-
panded the use of this model to include a broader spectrum
of severity of peripheral arterial occlusive disease in patients
treated only medically, those eligible for endovascular pro-
cedures, and those deemed to require primary amputa-
tion.13 Preliminary experience with this Markov model
favored more use of angioplasty and amputations and less
use of conservative medical therapy than proposed by the
701
JOURNAL OF VASCULAR SURGERY
October 2007702 Brothers, Robison, and Elliottvascular surgeons, although the actual treatment provided
frequently did not follow the preference of the decision
analysis model. This study represents an extension of that
preliminary experience, with specific objectives of deter-
mining whether theMarkovmodel could accurately predict
the actual quality of life experienced by these patients
according to their type of intervention and whether this
intervention resulted in an improvement in patient quality
of life.
METHODS
Study entry. All patients referred for evaluation of
signs and symptoms of chronic lower extremity ischemia to
the vascular surgery services at the Medical University of
South Carolina and the Ralph H. Johnson Department of
Veterans Affairs Medical Center over a 28-month period
were screened for participation in this prospective study.
Inclusion criteria included the presence of symptomatic
arterial occlusive disease as manifested by intermittent clau-
dication, resting ischemia pain, or ischemic tissue loss with
ulcers or gangrene. Exclusion criteria included the inability
of the patient, by his or her own admission, to adequately
comprehend the study. The experimental protocol was
approved by the institutional review board and performed
in accordance with institutional guidelines, which are in
accordance with the Helsinki Declaration of 1975. In-
formed consent was obtained from all patients after being
seen in consultation by one of the three participating vas-
cular surgeons. After enrollment, patients were randomized
by computerized random-number generation for their at-
tending surgeon to be made aware or remain unaware of
the results of decision analysis with theMarkov model. This
article describes the follow-up and quality-of-life data from
this group of patients previously reported.13 Enrollment
occurred between July 1999 andNovember 2001, with the
final 12-month evaluation completed in November 2002.
Decision-analysis model. Patient-specific utility val-
ues were assessed before surgery and at 4 and 12 months
after surgery by using visual analog scales and time trade-off
methods.10 The probabilities of success for the various
potential outcomes in the model were estimated before
surgery for each patient by the responsible attending sur-
geon. The mean, range, and standard deviation for each of
the utility values and probability estimates used in the
decision analysis model are included in Appendix Tables I
and II (online only). Individualized decision analysis con-
sisted of a Markov model constructed using the DATA 3.5
software package (TreeAge Software Inc, Williamston,
Mass). Four therapeutic interventions were considered by
the computer model: primary amputation, bypass opera-
tion, percutaneous balloon angioplasty, and medical man-
agement. This outcome was expressed in quality-adjusted
life-years.
The Markov decision analysis model has been previously
described.13 For the choice of primary amputation, four tran-
sitional states would be possible initially: healing of thewound
and the ability to ambulate with a prosthesis, healing of the
wound without the ability to ambulate, nonhealing of thewound, and perioperative death (Fig 1). Within a specified
cycle interval, patients would be predicted to have a finite
probability to either die or remain alive in the same state or,
alternatively, pass into another transitional state. For the
choice of bypass, initial transitional states included hemody-
namically satisfactory bypass with healing, unsatisfactory by-
pass without improvement and/or healing, early thrombosis
of the bypass, and perioperative death. Transitional states of
being ambulatory or nonambulatory with a healed amputa-
tion, for example, were not available as an initial result of the
bypass. However, they were included in this branch of the
decision tree, because they represent potential states after
amputation should the bypass not prove to be satisfactory and
not be revised. These states subsequently acted as clones of the
Primary Amputation subtree, as is indicated by the letter C,
thus allowing the extendeddecision tree to be illustratedmore
easily. For the choice of angioplasty, initial transitional states
included hemodynamically satisfactory angioplasty, unsatis-
factory angioplasty, and periprocedural death (Fig 2). The
initial transitional state associated with nonoperative medical
management assumed that the patient would remain the
same. This led to the possible outcomes of dying during the
course of the first cycle; requiring primary amputation, bypass
operation, or angioplasty; or remaining the same. The transi-
tional states associated with these other management options
are again included in this subtree. The cumulative time in each
transitional state earned quality-of-life points based on the
value placed on that state as determined by the utility assess-
ment. Utilities were discounted at a rate of 5% per annum
according to the authors’ best estimate of overall deteri-
oration in quality of life for patients of this age group
related to further aging but independent of vascular
disease. A disutility (negative utility) of 0.10 was as-
signed for the performance of each additional operation
and 0.08 for each additional angioplasty according to
the authors’ best estimate of the negative quality-of-life
effect of repeated interventions. The Markov rollback
used monthly cycles and was terminated when 99.9% of
the model was absorbed within the transitional state for
death or at a maximum of 600 cycles, corresponding to
50 years after initial intervention.
Quality of life and intervention. Immediately after
enrollment, generalized quality of life (Short Form-36;
SF-36) and disease-specific quality of life (Walking Impair-
ment Questionnaire [WIQ], value range, 0-70) were en-
tered by patients, supervised by a trained registered nurse,
on a touch-screen computer. Individual health concept
items of the SF-36, which range from 0 to 100, are specif-
ically weighted and combined to yield overall Physical and
Mental Component Scores, with mean (range) values of
43.5 (8-59) and 52.6 (21-74) for the US general popula-
tion aged 65 to 74 years.14 The initial plan for treatment
was recorded during the initial visit, and the final treatment
plan was recorded 1 week later, after the surgeon was
informed or not informed (according to randomization) of
the predictions of theMarkov model. Quality-of-life assess-
ments were repeated at 4 months and at 1 year after
enrollment by using the same tools as described previously.
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mean and standard deviation for demographic and patient
history data. Correlation of data was performed by using
Pearson two-tailed correlation analysis. Comparisons of
individual interval data were assessed by using t tests or
analysis of variance. Proportional data were compared by
using 2 tests. Agreement between models, decisions, and
Fig 1. Markov subtrees for primary amputation and
amputation reflect the potential for these outcomes. Cir
angioplasty. #Remaining outcome probability calculatedinterventions was assessed by using the  statistic.RESULTS
From July 1999 through November 2001, 214 pa-
tients were screened, 208 gave consent, and 205 were
enrolled with data available. The average patient age at
enrollment was 63 15 years (mean SD). Most patients
were white (58%) and male (70%). The most severe symp-
tom of peripheral vascular disease was claudication in 58%,
ss operation. Transitional states for amputation and
indicates a clone of named subtrees for amputation or
residual from the probability of all other events.bypa
cled C
as arest pain in 38%, and tissue loss in 14%. A minority of
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bypass operation (28%) or prior major amputation (7%),
whereas 32% had a family history of amputation for vascular
disease. Twenty-four patients died during the first year of
follow-up.
The types of operation recommended by the Markov
model and those actually performed have previously been
Fig 2. Markov subtrees for angioplasty and nonoperat
bypass, and angioplasty reflect the potential for these o
amputation, bypass, or angioplasty. #Remaining outcom
other events.reported.13 To summarize, the optimal treatments pre-dicted by decision analysis differed significantly from the
surgeon’s initial plan and consisted of bypass for 30% and
29% for the model and surgeon plan, respectively; angio-
plasty for 28% and 11%; amputation for 8% and 6%; and
medical management for 34% and 54% (agreement, 50%;
  0.28). Patients for whom the model agreed with the
surgeon’s initial plan were less likely to undergo bypass
edical management. Transitional states for amputation,
es. Circled C indicates a clone of named subtrees for
ability calculated as a residual from the probability of allive m
utcom
e prob(13% vs 30%; P .01). The study was originally designed to
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sults might alter the treatment plan, but this hypothesis
could not be proven. Surgeon awareness of the decision
model results did not alter the verbalized final plan, but it
did trend toward less frequent use of bypass. The primary
intervention actually performed consisted of amputation
for 9, bypass for 42, angioplasty for 8, and medical treat-
ment for 146 patients.
Follow-up quality-of-life data were not included in the
short-term report, but they can now be reported. Higher
SF-36 values indicate better quality of life. In contrast,
because higher WIQ values indicate greater impairment in
walking, correlations would be expected to be negative to
be predictive. In fact, the ability of the model to predict the
WIQ was weak (r  0.08). For the entire cohort of
patients, no improvements in mean overall patient quality
of life measured by the generalized SF-36 or disease-
specific WIQ were noted 12 months after counseling and
treatment by the vascular surgeons (Table I). Bodily Pain
was the only individual SF-36 category to improve (40 
23 vs 49  25; P  .03), whereas observed changes in
Physical Functioning (27  19 vs 22  16; P  .36) were
not significant. Improvements in Bodily Pain were more
likely to be observed among patients with limb-threatening
symptoms (68  25 vs 37  23; P  .02) compared with
patients presenting with claudication (41 24 vs 44 23;
P  .4). This was also observed for patients undergoing
bypass (60  29 vs 31  22; P  .02). Despite experienc-
ing a significant improvement in Bodily Pain (54  26 vs
37  22; P  .01) not observed among men (40  24 vs
43  23; P  .5), at 1 year WIQ was worse for women
compared with men (49  21 vs 37  22; P  .01).
One year after enrollment in the study, a significant
correlation was observed between many of the SF-36
quality-of-life parameters and the quality of life predicted at
Table I. For the entire cohort, change in generalized
(Short Form-36; SF-36) and disease-specific (Walking
Impairment Questionnaire; WIQ) variables after
patient enrollment
Variable Baseline 4 mo 12 mo
Bodily Pain 40  23 47  25 49  25*
Energy/Fatigue 40  21 45  23 43  19
Social Function 62  30 60  28 63  27
Mental Health 69  22 69  20 69  19
Role-Physical 21  30 24  36 30  38
Physical Functioning 27  19 28  23 22  16
General Health 47  21 46  19 43  19
Role-Emotional 64  44 66  46 58  45
Physical Component Score 27  8 28  9 28  8
Mental Component Score 51  12 51  11 51  11
Walking Impairment
Questionnaire 39  22 35  22 39  23
Higher SF-36 values indicate better quality of life, whereas higher WIQ
values indicate greater impairment in walking.
Data are mean  SD.
*P  .05 compared with baseline.baseline by the Markov model for the intervention that thepatient subsequently received (Table II). Clearly, predic-
tions of outcome by the model rely heavily on the method
of utility analysis chosen, as confirmed in our previous
study.13 The visual analog scale seems to be the simplest
and has the highest level of patient comprehension. Fur-
thermore, because use of the visual analog scale to provide
the utility assessment for the model seemed to correlate
better with actual quality of life, the visual analog scale was
used to determine how the model compared with the
surgeon’s treatment. It is noteworthy that when the sur-
geon’s treatment was incongruent with the Markov model,
patients were more likely to report a poorer Physical Com-
ponent Score quality of life both at baseline (28  9 vs
25  7; P .01) and at 1 year (25  8 vs 29  8; P  .01;
Table III). As previously reported, most disagreement was
on whether to offer bypass operation, which was the initial
intervention performed 30% of the time when the model
and surgeons were in agreement but only 13% of the time
when the two disagreed (P  .01). Aggressive surgical
management did not always seem to benefit patient quality
of life at 1 year as measured by these assessment tools.
DISCUSSION
Over the last decade, there has been increasing interest
in demonstrating that interventions performed in patients
with peripheral arterial disease do improve the quality of life
for those patients.4,15-18 Operative revascularization has
been found to be superior to primary amputation in many
studies.19-25 Such observations have not always been con-
sistent, because others have minimized the quality-of-life
benefit from revascularization for leg ischemia.5,15,17 Ben-
efits are often delayed during the recovery period from
operation.26 Indeed, few patients report feeling back to
their normal baseline level of health for the first 6 months
after infrainguinal bypass.20 Concurrent medical illness and
complex personal, financial, and social factors may distract
Table II. Quality of life predicted by the Markov model
by using patient-derived individualized visual analog scale
(VAS) or time trade-off (TTO) utility values correlated
with actual measured (Short Form-36) quality of life 12
months later
Variable VAS (r) TTO (r)
Bodily Pain 0.33* 0.11
Energy/Fatigue 0.44* 0.26
Social Function 0.30* 0.14
Mental Health 0.42* 0.02
Role-Physical 0.24 0.19
Physical Functioning 0.29* 0.09
General Health 0.31* 0.11
Role-Emotional 0.24 0.12
Physical Component Score 0.23 0.15
Mental Component Score 0.32* 0.00
Walking Impairment Questionnaire 0.08 0.05
Data are mean  SD.
*P  .05 by two-tailed test of significance.them from any perceived improvement in quality of life. By
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high. Two of three patients believe that their ability to
perform daily activities, leg pain, and walking ability will
improve, whereas most have a poor understanding of their
own long-term survival.27 These patients seem willing to
undertake significant operative risk with, perhaps, unrealis-
tic expectations for the achievable results.
Several authors have reported the development of stan-
dardized algorithms for treatment of peripheral arterial
disease. Some may be limited to specific clinical scenarios,
such as defining the conditions under which to perform
angioplasty with or without a covered stent vs bypass in
elderly patients according to the location and length of the
stenosis.7 By this algorithm, longer occlusions would be
bypassed and shorter stenoses in the femoral and popliteal
arteries would be managed by a covered stent. Other algo-
rithms are much more broad in scope and, thereby, more
clinically useful. The Lower Extremity Grading System
(LEGS) score favors primary amputation in patients with
lower pre-existing functional status, more medical comor-
bidities, compromised venous conduit, and (paradoxically)
less severe ischemia and a shorter extent of disease.28 Open
surgical revascularization is offered for good-risk patients
with fewer medical comorbidities who are ambulatory at
the time of presentation and exhibit more extensive arterial
involvement. Endovascular techniques are generally con-
sidered best suited for patients residing between these
extremes.6 Application of this relatively simple system of
interventional standardization has demonstrated excellent
results, including significant improvement in SF-36 patient
quality of life. Although these results are quite encourag-
ing, we have chosen a different approach—namely, the
burgeoning science of decision analysis geared toward in-
Table III. Change in generalized (Short Form-36) and
disease-specific (Walking Impairment Questionnaire)
variables according to agreement of the surgeon’s plan
with the model recommendation
Variable Baseline 4 mo 12 mo
Bodily Pain
Agree with model 43  24 47  23 47  21
Disagree with model 35  22* 47  27 48  32
Role-Physical
Agree with model 25  33 28  39 35  39
Disagree with model 17  27 18  31 19  34
Physical Functioning
Agree with model 32  21 32  23 24  16
Disagree with model 22  16 23  22 18  16
Physical Component Score
Agree with model 28  9 29  9 29  8
Disagree with model 25  7* 27  9 25  8*
Walking Impairment
Questionnaire
Agree with model 32  21 32  20 36  23
Disagree with model 48  21 39  26 48  24
Data are mean  SD.
*P  .05, “agree” vs “disagree.”dividual patients.Decision analysis has frequently been used to justify the
benefits of intervention in large populations of patients
with peripheral arterial occlusive disease of the lower ex-
tremities, but it has rarely been used clinically as a tool to
aid in the decision-making process.29-31 Formal decision
analysis combines the probabilities of various potential
outcomes of an intervention with the value of these out-
comes to patients.8 This type of analysis goes beyond
physician assessment of the patient’s level of function as a
proxy for their quality of life, and it actually incorporates
patient values and preferences for outcome. The greatest
challenge for decision analysis is accurate and fair assess-
ment of patient utility value scores.32 Utility values are
heavily influenced during the process of assessment, so that
utility values elicited by using different assessment strate-
gies may not be directly comparable.33,34 It has been
shown that utility values are best derived from the patients
themselves, because values derived from either treating
surgeons or patient surrogates inaccurately predict the pa-
tient’s actual views.35-37 The challenge of accurate deriva-
tion of patient utility values remains a controversial yet
critical component to the success of the model. Because it
correlates most directly with patient quality of life and
because it seems to be comprehensible to most patients, we
have chosen to use utility values derived by the visual analog
scale. The Markov model is also quite dependent on the
accuracy of the estimates of probability for various out-
comes of intervention. Algorithms derived from large da-
tabases such as the National Surgical Quality Improvement
Project may improve the accuracy of this estimate, at least
regarding mortality. The evolution of endovascular means
to manage increasingly complex peripheral vascular prob-
lems will also affect the estimated rate of success for these
procedures, such that the “angioplasty” option might bet-
ter be considered “endovascular.” Fundamentally, to dem-
onstrate the validity of the individualized Markov decision
analysis model, we must first show it to accurately predict
the actual quality of life experienced by the patient as
measured by generalized and disease-specific instruments.
In fact, this study has demonstrated that a Markov decision
model can be predictive of the quality of life after interven-
tion for these patients, although that ability is limited, with
even the highest correlation (r  0.44), with the Energy
and Fatigue component only expressing a 20% predictive
value. It is interesting to note that when the treatment
provided followed the Markov model, patients reported a
better quality of life at 1 year. This observation suggests
that the lack of congruency between the model and the
surgeon’s initial plan identifies a group of patients who have
the most to gain by reconsidering a different course of
treatment.
However, it is especially noteworthy that these obser-
vations suggest that regardless of intervention, the effects
on overall patient quality-of-life improvement are relatively
minute. This is somewhat at odds with the LEGS report,
although their study included only patients who were can-
didates for intervention and not conservative medical ther-
apy alone.28 In fact, compared with our observations, their
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baseline in the SF-36 categories of Social Function, Role
Emotional, Mental Health, and General Health, among
others. In this study, improvement in quality of life was
limited to those patients with the most severe symptoms
and those undergoing bypass operations. The fact that
most of our patients did not undergo direct intervention
may well affect the lack of greater improvement in the
group overall. Although only 29% had direct intervention,
the remainder were followed up medically, which is cer-
tainly an important option for patients referred with vascu-
lar disease. In fact, much of the disagreement between the
surgeon’s plan and the model’s recommendation was that
the surgeon recommended medical therapy far more often,
whereas the model suggested either amputation or angio-
plasty. It is across these broad options for treatment that the
model may be most useful.
The WIQ may be more sensitive to patients with clau-
dication and less so for limb-threatening ischemia, and it
has recently been confirmed that the SF-36 is less sensitive
for detecting patient changes after intervention for chronic
lower limb ischemia compared with other measures such as
the Nottingham Health Profile or the VascuQol.38,39
These quality-of-life indicators are disease specific and,
therefore, more sensitive to vascular disease. Had we
used these tools in this study, it is assumed that a greater
difference would have been detected as a result of direct
intervention or even medical therapy. However, because
these tools are much less generalizable for purposes of
comparison to other disease states in terms of overall
value gained, it can be argued that the need to use
alternative measures to detect improvement simply rein-
forces the original observation that the effects on overall
patient quality of life are relatively small. This study
identified Bodily Pain to be the only parameter that
consistently improved, and even then it did so only in
patients with the most severe symptoms or after bypass.
Although it may be assumed that most surgeons believe
that the effect of our interventions is great, these obser-
vations should help put the value of our interventions
into perspective.
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Dr Brothers. Certainly, we do approach things a little bit
differently down in the Low Country compared with our es-
teemed sister institution up in the Piedmont. I would also argue
that our patients may be somewhat different as well. Clearly, this
number of 206 patients over a 20-month period does not
encompass all of the patients we see in consultation. In fact,
most of the patients that we see in consultation are referred
through the inpatient or direct referral hospital transfer, so that
is probably is why many patients that we intervene on were not
included in this study. Second, within the screening group, I
would also mention that one of the requirements was the
perceived ability for our patients to be able to understand
abstract concepts about what we were doing and cooperate with
the touch screen. Many of our patients were perhaps deemedRegarding whether we have altered our indications for angio-
plasty in response to this study, our group has become much
more willing to consider angioplasty and other methods of
endovascular revascularization compared with the practices de-
scribed in this cohort recruited approximately 5 years ago. I
certainly am in agreement that trying to ascertain SF-36 data or
other disease-specific assessments of quality of life can be quite
complex in these patients, but I do not share your pessimism
that there is little benefit from an attempt to do so. In fact, I
think it is vital that as we look at the results our interventions,
whatever they may be, we continue to pay particular attention to
the patients’ quality of life, not just some other measure that
makes us feel justified as interventionalists, such as patency or
limb salvage, but rather how the patients feel about what we
have been able to help them accomplish.INVITED COMMENTARYMichael P. Lilly, MD, Baltimore, Md
The authors are to be commended for applying decision
analysis to the vexing problem of how to measure the efficacy of
treatment for symptomatic lower extremity atherosclerosis and for
the choice to include in this analysis the majority of such patients—
those with milder symptoms. Despite the limited data available to
calibrate the outcome-based probability parameters, the authors’
model was fairly accurate in predicting the quality of life (QOL)
and walking status of patients at 1 year. The truly disappointing
findings were the actual QOL data: (1) significant benefit was
noted only for those with the most severe disease who had surgical
intervention and (2) medical therapy had no impact on QOL
metrics. While one can quibble about whether other QOL ques-
tionnaires may have shown different results in this cohort, the data
are sobering. Data like these have led health care payers, regulatory
agencies, and patients themselves to question the efficacy of man-
agement approaches crafted over decades by vascular specialists.
They also challenge our claim to superior knowledge and expertise
in this arena.
How should vascular surgeons respond? First, we must acceptand rates of limb salvage and survival may not capture the out-
comes most important to our patients, especially those with mild
disease. Second, we must be committed to prospective analysis of
outcomes of our patients with lower extremity atherosclerosis
across the full spectrum of disease and apply the most modern
methods of analysis to this task. The authors point out that better
risk-adjusted outcomes data are needed to more accurately cali-
brate models such as theirs. It may be that accurate prospective
QOL data on percutaneous treatments will provide a valid ratio-
nale for the application of these techniques to subsets of patients
with earlier stages of disease. Third, we must take an active role in
the development and testing of new methods of treatment for
patients with mild disease. The ineffectiveness of current noninter-
ventional therapy from the patient’s perspective is clear from this
study. Finally, vascular surgeons must be open to the idea of
incorporating data from a model such as this into actual clinical
decisionmaking. Such an application is premature at this point, but
data-driven management protocols or guidelines are on the way,
and vascular experts must contribute fundamentally to their devel-
opment for the benefit of both our patients and our specialty.
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Variable VAS
Bypass successful 0.67 (0.25; 0.25-0.86
Stayed the same 0.53 (0.26; 0.19-0.72
Bypass failed 0.42 (0.26; 0.06-075
Amputate, ambulate 0.39 (0.28; 0.10-0.65
Amputate, nonambulate 0.26 (0.25; 0.05-0.65
Amputate, nonhealed 0.20 (0.24; 0.02-0.52
Data are mean (SD; range).
*Paired t-test.scores derived from individual patients
TTO P value*
) 0.85 (0.26; 0.4-1.0) .001
) 0.77 (0.31; 0.3-0.9) .001
) 0.71 (0.35; 0.1-0.9) .001
) 0.71 (0.35; 0.2-0.9) .001
) 0.60 (0.39; 0.2-0.8) .001
) 0.52 (0.41; 0.1-0.8) .001
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Potential outcome Mean SD (range)
Patient mortality (annual)* 0.13 0.04 (0.05-0.50)
Primary amputation
Amputation healed, ambulatory 0.46 0.18 (0.00-0.90)
Amputation not healed 0.11 0.04 (0.01-0.40)
Death from amputation/reamputation 0.04 0.03 (0.01-0.30)
Stay healed ambulatory* 0.15 0.19 (0.02-1.00)
Wound breakdown* 0.10 0.02 (0.05-0.30)
Reamputation healed, ambulatory 0.40 0.16 (0.00-0.75)
Reamputation not healed 0.11 0.04 (0.05-0.40)
Bypass operation
Bypass satisfactory 0.87 0.13 (0.02-0.98)
Early thrombosis after bypass* 0.14 0.14 (0.02-0.98)
Death from bypass/rebypass 0.03 0.05 (0.00-0.50)
Late thrombosis† 0.51 0.17 (0.02-0.95)
Amputation for unsatisfactory bypass 0.29 0.16 (0.01-0.90)
Rebypass satisfactory 0.77 0.14 (0.00-0.95)
Early thrombosis after rebypass 0.25 0.17 (0.00-0.99)
Angioplasty after bypass failure 0.10 0.06 (0.00-0.50)
Angioplasty
Angioplasty satisfactory 0.89 0.18 (0.00-0.99)
Early thrombosis after angioplasty* 0.44 0.31 (0.00-1.00)
Death from angioplasty/reangioplasty 0.01 0.01 (0.00-0.05)
Late thrombosis† 0.82 0.14 (0.20-1.00)
Reangioplasty satisfactory 0.16 0.12 (0.00-0.60)
Bypass for unsatisfactory angioplasty 0.85 0.21 (0.00-0.98)
Early thrombosis after reangioplasty 0.57 0.27 (0.00-1.00)
Nonoperative management
Symptoms do not worsen† 0.44 0.32 (0.00-0.95)
Delayed angioplasty* 0.16 0.19 (0.00-0.80)
Delayed bypass* 0.60 0.32 (0.00-1.00)
Data are mean (SD; range).
*One-year estimate.
†Five-year estimate. These estimates were used to derive monthly probability estimates.
